% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{SteinbergVorhoff:301713,
author = {H. L. Steinberg-Vorhoff and J. Haubold and S. Bauer and H.
Richly and J. T. Siveke$^*$ and J. Wimmer and L. Umutlu and
B. M. Schaarschmidt and J. M. Theysohn and J. M. Ludwig},
title = {{D}egradable {S}tarch {M}icrosphere {T}ransarterial
{C}hemoembolization as {S}alvage {T}herapy in {P}atients
with {U}veal {M}elanoma {L}iver {M}etastases.},
journal = {Journal of vascular and interventional radiology},
volume = {36},
number = {9},
issn = {1051-0443},
address = {Amsterdam [u.a.]},
publisher = {Elsevier},
reportid = {DKFZ-2025-01105},
pages = {1418-1426.e1},
year = {2025},
note = {2025 Sep;36(9):1418-1426.e1},
abstract = {To assess DSM-TACE retrospectively as salvage therapy in
patients with unresectable uveal melanoma (UM) liver
metastases and to identify prognostic factors for
survival.Fifty-five patients $(49.1\%$ male, median age 65
years) who underwent a median of two (range 1-12) DSM-TACE
treatments were included. Cox proportional hazard models for
uni- and multivariate analyses (hazard ratio, $95\%$
confidence interval [CI], p-value) and Kaplan-Meier analysis
were performed to determine the median overall survival and
time to progression (mOS/TTP; $95\%$ CI). Response
assessment was performed according to the RECIST 1.1
criteria.The median OS of the study cohort was 8.0 $(95\%$
CI: 6.7-9.3) months. Univariate analysis identified low
lactate dehydrogenase (LDH <2x the upper level of normal)
(0.26; 0.12-0.57, p<0.001), normal serum protein (0.32;
0.15-0.7, p=0.008), hepatic tumor burden $≤25\%$ (0.39;
0.19-0.78, p=0.007), and monthly tumor growth rate (TGR) ≤
$20\%$ before the first DSM-TACE (0.32; 0.14-0.7, p=0.005)
as predictors of prolonged mOS. Multivariate analysis
confirmed low LDH (mOS: 11.4 vs. 4.3 months, p=0.021) and
low TGR (mOS: 9.9 vs. 6.4 months, p=0.005) as independent
predictors. Median TTP was four months $(95\%CI:$ 3.1-5.7).
The best response observed was PR in $13.6\%,$ SD in
$65.9\%,$ and PD in $20.5\%,$ with mOS of 25 (13.5-31.6), 8
(7.1-9.8), and 4.4 (2.1-20.4) months, respectively.DSM-TACE
represents a salvage treatment option for UM patients with
liver metastases that can help control the tumor. Lower
pretreatment serum LDH levels and low TGR have been
associated with prolonged mOS. However, direct comparison
with alternative treatments is required.},
keywords = {Degradable starch microspheres (Other) / Liver metastases
(Other) / Transarterial chemoembolization (Other) / Tumor
growth rate (Other) / Uveal melanoma (Other)},
cin = {ED01},
ddc = {610},
cid = {I:(DE-He78)ED01-20160331},
pnm = {899 - ohne Topic (POF4-899)},
pid = {G:(DE-HGF)POF4-899},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:40436267},
doi = {10.1016/j.jvir.2025.05.020},
url = {https://inrepo02.dkfz.de/record/301713},
}